Keywords:
Benzathine benzylpenicillin (BPG); consumer perspective; penicillin; rheumatic fever; rheumatic heart disease; secondary prophylaxis; stakeholder perspective
Abstract:
Intramuscular (IM) injection of benzathine benzylpenicillin G (BPG) forms the cornerstone of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) secondary prophylaxis. BPG is available as either a low-cost powdered formulation or a costlier pre-filled suspension. Most of the global RHD burden lies in low- and middle-income countries, which rely on the powdered formulation.